159 related articles for article (PubMed ID: 36448227)
21. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
22. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
Shimony S; Liu Y; Valtis YK; Paolino JD; Place AE; Brunner AM; Weeks LD; Silverman LB; Vrooman LM; Neuberg DS; Stone RM; DeAngelo DJ; Luskin MR
Blood Adv; 2023 Apr; 7(7):1092-1102. PubMed ID: 36508268
[TBL] [Abstract][Full Text] [Related]
23. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
[TBL] [Abstract][Full Text] [Related]
24. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
[TBL] [Abstract][Full Text] [Related]
25. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
[TBL] [Abstract][Full Text] [Related]
26. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
28. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
30. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
31. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
32. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
33. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
34. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Curbo S; Karlsson A
Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
[TBL] [Abstract][Full Text] [Related]
35. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
[TBL] [Abstract][Full Text] [Related]
36. Nelarabine: efficacy in the treatment of clinical malignancies.
Roecker AM; Allison JC; Kisor DF
Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
[TBL] [Abstract][Full Text] [Related]
37. Nelarabine in the treatment of refractory T-cell malignancies.
Roecker AM; Stockert A; Kisor DF
Clin Med Insights Oncol; 2010 Dec; 4():133-41. PubMed ID: 21151585
[TBL] [Abstract][Full Text] [Related]
38. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
39. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
[TBL] [Abstract][Full Text] [Related]
40. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
